For the quarter ending 2025-09-30, SANA had $32,086K increase in cash & cash equivalents over the period. -$29,470K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -42,152 | -143,189 |
| Depreciation | 3,191 | 6,506 |
| Stock-based compensation expense | 5,476 | 13,651 |
| Change in the estimated fair value of contingent consideration | -1,991 | 8,164 |
| Change in the estimated fair value of success payment liabilities | 5,115 | 4,055 |
| Non-cash expense for operating lease right-of-use assets | 2,317 | 4,463 |
| Impairment of long-lived assets | 0 | 44,611 |
| Other non-cash items, net | 2,082 | 5,794 |
| Prepaid expenses and other assets | -1,121 | -740 |
| Operating lease right-of-use assets and liabilities | 1,458 | 81 |
| Accounts payable | -357 | -2,999 |
| Accrued expenses and other liabilities | 1,391 | -11,885 |
| Net cash used in operating activities | -29,429 | -81,758 |
| Purchases of marketable securities | 49,527 | 1,682 |
| Proceeds from maturities of marketable securities | 1,407 | 25,354 |
| Purchases of property and equipment | 41 | 24 |
| Proceeds from disposal of assets | 136 | 635 |
| Net cash used in investing activities | -48,025 | 24,283 |
| Proceeds from employee stock purchase plan and exercise of stock options | 157 | 1,460 |
| Proceeds related to common stock financings, net | 109,470 | 254 |
| Proceeds (principal payments), net for tenant improvement loan | -87 | -171 |
| Net cash provided by financing activities | 109,540 | 1,543 |
| Net decrease in cash, cash equivalents, and restricted cash | 32,086 | -55,932 |
| Cash and cash equivalents at beginning of period | 131,398 | - |
| Cash and cash equivalents at end of period | 107,552 | - |
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)